Skip to main content
Clinical Trials/ACTRN12605000170628
ACTRN12605000170628
Terminated
Phase 4

A placebo controlled study to test the effectiveness of atorvastatin and irbesartan on infarct size, cerebral perfusion, cerebral response to ischaemia and clinical outcome in acute ischaemic stroke

niversity of Western Australia0 sites200 target enrollmentAugust 17, 2005

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Acute Ischaemic Stroke
Sponsor
niversity of Western Australia
Enrollment
200
Status
Terminated
Last Updated
6 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
August 17, 2005
End Date
TBD
Last Updated
6 years ago
Study Type
Interventional
Sex
All

Investigators

Sponsor
niversity of Western Australia

Eligibility Criteria

Inclusion Criteria

  • All patients admitted within 72 hours of onset of symptoms will be eligible for trial entry, unless exclusion criteria are met.If a person is unable to provide informed consent the next of kin will be sought to provide consent. Patients regaining capacity will be free to continue in or withdraw from the trial.

Exclusion Criteria

  • Hypotension: Blood pressure less than 100mmHg systolic or 70mmHg diastolic. Hypertension (\>220 mmHg) or clinical imperative to lower blood pressure. Hyperkalaemia: \>5\.5 mmol/L. Finger prick or laboratory blood sugar level \> 13 mmol/L at baseline. Acute comorbid condition (such as myocardial ischaemia or sepsis). Active liver disease or unexplained elevation in transaminases. Already treated with ATRA, statin or more than one of an ACE inhibitor, non steroidal anti\-inflammatory, potassium sparing diuretic, potassium salt or cyclosporin. Premenopausal female. Renal impairment (defined as creatinine \>120 umol/L). History of sensitivity to statins, ATRA or contrast. Haemorrhage seen on initial CT.

Outcomes

Primary Outcomes

Not specified

Similar Trials